1398-9995/asset/olbannerleft.gif?v=1&s=2207070238298c1b0c4b1e73fa97140fa65e5f81)
1398-9995/asset/olbannerright.gif?v=1&s=c902da976bf6db24fc36ec0480207615a3d14921)
Increased levels of urinary leukotriene E4 in children with severe atopic eczema/dermatitis syndrome
Article first published online: 3 DEC 2004
DOI: 10.1111/j.1398-9995.2005.00658.x
Additional Information
How to Cite
Øymar, K. and Aksnes, L. (2005), Increased levels of urinary leukotriene E4 in children with severe atopic eczema/dermatitis syndrome. Allergy, 60: 86–89. doi: 10.1111/j.1398-9995.2005.00658.x
Publication History
- Issue published online: 3 DEC 2004
- Article first published online: 3 DEC 2004
- Accepted for publication 4 May 2004
- Abstract
- Article
- References
- Cited By
Keywords:
- atopic eczema/dermatitis syndrome;
- atopy;
- children;
- leukotriene E4;
- leukotrienes
Background: Leukotrienes are thought to play a role in the pathogenesis of atopic eczema/dermatitis syndrome (AEDS). Urinary leukotriene E4 (U-LTE4) is a marker of whole-body cysteinyl-leukotriene production.
Aims of the study: To evaluate the role of leukotrienes in children with AEDS by measuring levels of U-LTE4, and to evaluate whether levels of U-LTE4 may reflect disease activity and allergic sensitization in AEDS.
Methods: U-LTE4 was measured by enzyme-linked immunosorbent assay in 87 children with mild (n = 32), moderate (n = 34) and severe (n = 21) AEDS, as well as in 72 nonatopic healthy controls. Fifty-eight of the children with AEDS were sentitized to common allergens, and 29 were not.
Results: Levels of U-LTE4 were higher in children with severe AEDS (140; 66–166 μg/mmol creatinine, median; quartiles) than in controls (52; 30–90, P < 0.05), whereas levels of U-LTE4 in moderate and mild disease were similar to controls. U-LTE4 levels were similar in children with or without sensitization to common allergens, but severe AEDS children with sensitization had higher levels of U-LTE4 than those without sensitization.
Conclusion: The results suggest a role for leukotrienes in the pathogenesis of severe AEDS, and may support a role for leukotriene-antagonists in the treatment of this disorder. Levels of U-LTE4 may reflect the disease severity and sensitization to allergens in AEDS.